APA (7e ed.) Bronvermelding

Ryder, R., Holman, R., & Gwilt, M. (2016). This house believes that sulphonylureas should not be used routinely as second-line treatments for patients with type 2 diabetes. Association of British Clinical Diabetologists.

Chicago (17e ed.) Bronvermelding

Ryder, R., R. Holman, en M. Gwilt. This House Believes That Sulphonylureas Should Not Be Used Routinely as Second-line Treatments for Patients with Type 2 Diabetes. Association of British Clinical Diabetologists, 2016.

MLA (9e ed.) Bronvermelding

Ryder, R., et al. This House Believes That Sulphonylureas Should Not Be Used Routinely as Second-line Treatments for Patients with Type 2 Diabetes. Association of British Clinical Diabetologists, 2016.